<a href="https://laohu8.com/S/PMCB">PharmaCyte Biotech</a> Secures $7 Million Through Private Placement Led by Existing Investors
PharmaCyte Biotech Inc. has announced a $7 million capital raise through a securities purchase agreement with existing investors. The financing involves the sale of 7,000 shares of newly designated Series C convertible preferred stock, each valued at $1,000, convertible into 7,000,000 shares of common stock. Additionally, unregistered common stock purchase warrants are included, allowing the purchase of up to 7,000,000 shares of common stock. The private placement, led by GP Nurmenkari Inc. as the sole placement agent, is expected to close on or about August 19, 2025. This move is seen as a strong vote of confidence in PharmaCyte's future, enhancing its financial position and allowing the company to pursue strategic alternatives aimed at maximizing long-term shareholder returns.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250818528622) on August 18, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。